ROSELLA, KEYNOTE-B96, and ADCs Take Center Stage at SGO 2026: Expert Perspectives on the Meeting’s Most Impactful Data

The 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer brought a wave of practice-changing data to the field of gynecologic oncology. From two FDA-approved regimens in platinum-resistant ovarian cancer (PROC) presented in the opening plenary, to a closely watched phase 3 trial challenging the role of upfront chemotherapy in low-grade serous ovarian carcinoma (LGSOC), the meeting gave clinicians much to consider.